Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-12-10
2003-05-06
Kifle, Bruck (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06559314
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to a simple and industrially readily executable method of producing thiazolidine base and salts thereof.
BACKGROUND OF INVENTION
Thiazolidine can serve as an intermediate for the synthesis of aminoacyl and peptidyl thiazolidides, which have both a diagnostic and a therapeutic value as enzyme inhibitors [H.-U. DEMUTH, J. Enzyme Inhibition 3, 249 (1990)].
Since aminoacyl thiozolidides are suitable, inter alia, for the regulation of the blood sugar level in mammals, the preparation of these compounds and their parent materials using a cost-effective, commercially applicable process is of medical, pharmaceutical and economical interest [cf DE 19,616,486].
It is known that thiazolidine and thiazolidine derivatives can be obtained by refluxing aldehydes with aminoethyl sulfate or aminoethyl halides and sodium sulfide in aqueous solution under excess energy input over a period of several hours. The yields are ca 60% of theory [cf U.S. Pat. No. 4,584,407].
It is an object of the present invention, however, to provide a process for the production of thiazolidine base or the salts thereof in which no excess energy input is necessary.
SUMMARY OF THE INVENTION
The present invention now provides a process for the production of thiazolidine base and salts thereof which is characterized in that hexamethylenetetramine of formula (I) as shown in
FIG. 1
is caused to react with cyst amine or salts thereof of formula (II) as shown in FIG.
2
. in which X
(−)
denotes an acid residue, X
(−)
being preferably a halide or sulfate.
It is extremely surprising to find that this process gives the free base thiazolidine and salts thereof in high yields of very pure substance without it being necessary to apply excess quantities of heat during the reaction. This constitutes a cost-effective and technological advantage of the process of the invention particularly as regards the industrial production of thiazolidine [cf EP 0,054,409].
DETAILED DESCRIPTION
In the present invention, the reaction can take place, eg, in a polar solvent such as an alcohol. Preferred solvents are methanol and/or ethanol.
Another economical and technological advantage of the process of the invention for the industrial production of thiazolidine is the fact that hexamethylenetetramine is acceptable as regards the pharmaceutical use of the secondary products of thiazotidine, since it is pharmaceutically acceptable: for many years it has been used as a urine disinfectant and for food preservation [cf Mutschler, Arzneimittelwirkungen, pp. 572 et seq., Stuttgart: Wissenschaftliche Verlagsgs. (1986)].
Preferably, ammonia is used as the initial batch and/or is added during the reaction. By this means, synthesis can be carried to the stage of the free base in a single step [cf S. Ratner, H. T. Clarke, J. Am. Chem. Soc. 59, pp 200-206 (1937)] so that additional complicated and expensive reaction stages can be omitted.
The process of the invention, which is designed for both laboratory-scale and commercial-scale applications, is carried out, for example, by adding hexamethylenetetramine to a preferably methanolic solution of a cysteamine salt all at once or in a number of portions, as solid matter or dissolved in a solvent. The mixture can be stirred for several hours at room temperature, or it may be stirred at temperatures around 30-35° C. The stated dosing procedure can take place in reverse order if desired.
The process of the invention must not necessarily be carried out under a blanket of inert gas as in other processes [cf EP 0,695,744].
The thiazolidine produced by the process of the invention can be used as starting material for the production of pharmaceutically useful active substances. The invention is illustrated with reference to the following example.
REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 6006753 (1999-12-01), Efendic
patent: DT 25 42598 (1976-04-01), None
patent: 196 16 486 (1997-10-01), None
patent: 2085665 (1971-03-01), None
patent: 2696740 (1992-10-01), None
patent: 4334357 (1992-11-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO00/01849 (2000-01-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO01/62266 (2001-08-01), None
Campbell, I.W. New Antidiabetic Drugs, ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, “Sulphonylureas and metformin: efficacy and inadequacy”. 3:33-51 (1990).
Mercla Index, 11thEdition, p. 934.
Martindale The Extra Pharmacopeia, 30thEdition, Pharmaceutial Press, 1993, p. 1619.
Chemical Abstracts, vol. 115. No. 15, Oct. 14, 1991 Columbus, Ohio, US; abstract No. 149947q, Schoen Ekkehard Et Al: “Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes”.
Chemical Abstracts, vol. 126, No. 2, Jan. 13, 1997 Columbus, Ohio, US; abstract No. 16161j, Stoeckel A. Et Al: “Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides”.
Chemical Abstracts, vol. 118, No. 25, Jun. 21, 1993 Columbus, Ohio, US; abstract No. 255342k, Hosoda, et al, “Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors”, Nov. 1992 (Nov. 20, 1992).
Arai Et Al: “Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain” Chemical and Pharmaceutical Bulletin., Bd. 41, No. 9, 1993, pp. 1583-1588.
J. Lin et al.: “Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-O-hydroxylamine peptidomimetics” Proceedings of the National Academy of Sciences of USA, vol. 95, Nov. 1998, pp. 14020-14024.
Korom, S., et al “Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients”, Transplantation vol. 63, 1495-1500 No. 10 (1997).
Tanka, S., et al., “Supperession of arthritis by the inhibitors of dipeptidyl peptidase IV”. Int. J. Immunopharmacol, vol. 19, No. 1 pp. 15-24, 1997.
Mentlein, R., et al., “Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV”. Regul. Pept. 49, 133-144(1993).
Wetzl, W., et al., “Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes”. Neuropeptides, 31, 41-45 (1997).
Amasheh, S., et al., “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus Laevis oocytes”. J. Physiol. 504, 169-174 (1997).
Durinx, C.; et al.; “Reference Values for Plasma Dipepidyl-Pepidase IV activity and their Association with Other Laboratory Parameters”. Clin Chem Lab Med 2001, Feb.; 39 (2) :155-9, 1 page.
Gossrau, R.; “Cytochemistry of Membrane Proteases”. Histochem J, 1985, Jul.; 17 (7) :737-71, 1 page.
Hahn, T.; et al.; “Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae”. Acta Histochem 1993, Dec., 1995 (2) :185-92, 1 page.
Heymann, E.; et al.; “Has Dipeptidyl Peptidase IV an Effort on Blood Pressure and Coagulation.” Klin Wochenschr, 1984, Jan., 2;62 (1) :2-10, 1 page.
Magyar, C.E.; et al.; “Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension.” Am J Physiol Renal Physiol, 2000, Aug.; 279 (2) :F358-69, 1 page.
Papies, B.; et al.; “Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ
Demuth Hans-Ulrich
Kruber Susanne
Brown Rudnick Berlack & Israels LLP
Kifle Bruck
Probiodrug (AG)
Saunders Thomas M.
LandOfFree
Method for the production of thiazolidin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the production of thiazolidin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the production of thiazolidin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3027148